Iopamidol

Summary

Iopamidol (CHEMBL1200932) is an approved small-molecule radioopaque medium (ATC V08AB04); indicated across 6 conditions including glioma and hypothalamic neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V08AB04
• Indications: 6 conditions
• Clinical trials: 82
• Chemistry: 777.1 Da · C17H22I3N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200932
Name	Iopamidol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	65492
ChEBI	CHEBI:31711
ATC	V08AB04
Molecular formula	C17H22I3N3O8
Molecular weight	777.1
InChIKey	XQZXYNRDCRIARQ-LURJTMIESA-N

SMILES: C[C@@H](C(=O)NC1=C(C(=C(C(=C1I)C(=O)NC(CO)CO)I)C(=O)NC(CO)CO)I)O

IUPAC name: 1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-[[(2S)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide

ChEBI definition: A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.

Pharmacological roles (ChEBI): radioopaque medium.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: Iopamidol, Iopamidol-200, Iopamidol-250, Iopamidol-300, Iopamidol-370, Iopamiron, Isovue, Isovue-128, Isovue-200, Isovue-250, Isovue-300, Isovue-370

Patent coverage: 2,862 distinct patent families (9,866 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.85	Potency	1412	nM	CHEMBL_ACT_3642165

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
glioma	4	MONDO:0021042	EFO:0005543
hypothalamic neoplasm	4	MONDO:0006799	EFO:1000979
breast neoplasm	1	MONDO:0021100	MONDO:0007254
renal cell carcinoma	0	MONDO:0005086	EFO:0000681
urothelial carcinoma	0	MONDO:0040679	EFO:0008528

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 82.

Phase distribution

Phase	Trials
PHASE4	28
Not specified	24
PHASE1	17
PHASE2	6
PHASE3	3
EARLY_PHASE1	3
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05967117	PHASE4	RECRUITING	Chest CT Using Low-concentration Iodine Contrast Media
NCT06709521	PHASE4	RECRUITING	Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)
NCT00209417	PHASE4	TERMINATED	Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography
NCT00289029	PHASE4	COMPLETED	A Study of Two Iodinated Contrast Agents in Renally Impaired Patients Undergoing Cardiac Angiography
NCT00289614	PHASE4	COMPLETED	Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
NCT00292487	PHASE4	COMPLETED	Patients With Renal Impairment Undergoing CT
NCT00351754	PHASE4	COMPLETED	Detection of Pulmonary Embolism With CECT
NCT00740207	PHASE4	COMPLETED	Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
NCT01075217	PHASE4	COMPLETED	Isovue in Peripheral Digital Subtraction Angiography (DSA)
NCT01136876	PHASE4	COMPLETED	Kidney Damage in Patients With Moderate Fall in eGFR
NCT01136915	PHASE4	TERMINATED	Kidney Damage In Patients With Severe Fall In eGFR
NCT01376089	PHASE4	COMPLETED	Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen/Pelvis
NCT01475097	PHASE4	COMPLETED	Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
NCT02040285	PHASE4	COMPLETED	Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)
NCT02170688	PHASE4	COMPLETED	Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT
NCT02246998	PHASE4	COMPLETED	Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults
NCT02291718	PHASE4	COMPLETED	Thoracoabdominal Arortic CTA Study
NCT02467075	PHASE4	TERMINATED	Double-Blind Placebo-Controlled CIN Trial
NCT02522338	PHASE4	COMPLETED	Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance
NCT03384979	PHASE4	COMPLETED	Optimization of Contrast Agent Dose in CT With Lean Body Weight
NCT03415997	PHASE4	COMPLETED	Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight
NCT03557385	PHASE4	COMPLETED	Adenosine Contrast CorrELations in Evaluating RevAscularizaTION
NCT03631771	PHASE4	WITHDRAWN	Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NCT03779906	PHASE4	TERMINATED	Thyroid Function of Pediatric Subjects Following Isovue® Administration
NCT04113109	PHASE4	COMPLETED	Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
NCT04649229	PHASE4	COMPLETED	Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
NCT04742816	PHASE4	COMPLETED	Renal Effects of Hormones/Biomarkers in Transgender PrEP Recipients
NCT05065073	PHASE4	UNKNOWN	Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography
NCT02050269	PHASE3	COMPLETED	Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study
NCT02171247	PHASE3	COMPLETED	Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)
NCT02961478	PHASE3	UNKNOWN	Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure
NCT06411795	PHASE2	RECRUITING	Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
NCT00558792	PHASE2	COMPLETED	Coronary MDCTA With Iopamidol Injection 370
NCT01672996	PHASE1/PHASE2	COMPLETED	Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers
NCT02772276	PHASE2	COMPLETED	Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types
NCT04627831	PHASE2	WITHDRAWN	Comparison of Captisol-Enabled™ Iohexol and Omnipaque™ in Patients With Impaired Renal Function Undergoing Coronary Angiography
NCT05672134	PHASE2	COMPLETED	Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
NCT06820320	PHASE2	COMPLETED	Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
NCT03997370	PHASE1	ACTIVE_NOT_RECRUITING	Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
NCT05065372	PHASE1	RECRUITING	MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).